{
    "clinical_study": {
        "@rank": "90575", 
        "acronym": "TAXYNERGY", 
        "arm_group": [
            {
                "arm_group_label": "Docetaxel plus prednisone", 
                "arm_group_type": "Experimental", 
                "description": "docetaxel 75mg/m2 will be administered intravenously every 3 weeks, plus prednisone 10 mg orally given daily.  Patients who do achieve \u226530% PSA reduction from baseline by cycle 4, will continue with docetaxel until progression, death, unacceptable toxicity or patient's refusal of further study treatment.  Patients who do not achieve \u226530% PSA reduction from baseline by cycle 4 will switch chemotherapy to receive cabazitaxel plus prednisone"
            }, 
            {
                "arm_group_label": "Cabazitaxel plus prednisone", 
                "arm_group_type": "Experimental", 
                "description": "cabazitaxel 25mg/m2 will be administered intravenously  every 3 weeks, plus prednisone 10 mg orally given daily.  Patients who do achieve \u226530% PSA reduction from baseline by cycle 4, will continue with cabazitaxel until progression, death, unacceptable toxicity or patient's refusal of further study treatment. Patients who do not achieve \u226530% PSA reduction from baseline by cycle 4 will switch chemotherapy to receive docetaxel plus prednisone"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objectives: - To explore the benefit of an early switch from docetaxel/prednisone to\n      cabazitaxel/ prednisone in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)\n      who do not achieve \u226530% prostate-specific antigen (PSA) decline from baseline by cycle 4\n      with the initial docetaxel treatment. - To evaluate the circulating tumor cells (CTCs) with\n      clinical response/resistance to docetaxel or cabazitaxel treatment  Secondary Objectives: -\n      To assess efficacy and safety of the two treatment strategies, switch from\n      cabazitaxel/prednisone to docetaxel/prednisone and docetaxel/prednisone to\n      cabazitaxel/prednisone. - To evaluate efficacy in patients receiving initial taxane\n      treatment before the switch and efficacy under the alternate taxane after the switch within\n      each initial treatment group."
        }, 
        "brief_title": "Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer Metastatic", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be treated until progressive disease, unacceptable toxicity, death or\n      patient's refusal of further study treatment. All patients will be followed until death or\n      the study cutoff date, whichever comes first. Study cut-off will be 6 months after the last\n      patient last treatment. Patients alive at the cut-off date will be followed for overall\n      survival.  Collection of survival data after the cut-off date will be done every year for a\n      maximum of 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Histologically- or cytologically-confirmed prostate adenocarcinoma with documented\n             distant metastases (M1 disease)\n\n          -  Progressive disease while receiving hormonal therapy or after surgical castration\n\n          -  Effective castration (serum testosterone levels \u226450 ng/dL) by orchiectomy and/or\n             luteinizing hormone releasing hormone agonists or antagonist with or without\n             anti-androgens.\n\n        Exclusion criteria:\n\n          -  Prior chemotherapy for prostate cancer, except estramustine and adjuvant/neoadjuvant\n             treatment completed >3 years ago. Prior treatment with sipuleucel-T immunotherapy is\n             allowed at the condition patient did not received prior chemotherapy.\n\n          -  Less than 28 days elapsed from prior treatment with estramustine, radiotherapy or\n             surgery to the time of random allocation.\n\n          -  Prior beta isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of\n             bone marrow.\n\n          -  Adverse events (excluding alopecia and those listed in the specific exclusion\n             criteria) from any prior anticancer therapy of grade >1(National Cancer Institute\n             Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) at the time of\n             random allocation.\n\n          -  Less than 18 years of age\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status >2.\n\n          -  History of brain metastases, uncontrolled spinal cord compression, or carcinomatous\n             meningitis or new evidence of brain or leptomeningeal disease.\n\n          -  Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial\n             (pTis, pTa and pT1) bladder cancer are allowed, as well as any other cancer for which\n             chemotherapy has been completed \u22653 years ago and from which the patient has been\n             disease-free for \u22653 years.\n\n          -  Participation in another clinical trial and any concurrent treatment with any\n             investigational drug within 30 days prior to random allocation.\n\n          -  Any of the following within 6 months prior to study enrollment: myocardial\n             infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,\n             New York Heart Association (NYHA) class III or IV congestive heart failure, stroke or\n             transient ischemic attack.\n\n          -  Any of the following within 3 months prior to random allocation: treatment resistant\n             peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory\n             bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled\n             thromboembolic event.\n\n          -  Acquired immunodeficiency syndrome (AIDS)-related illnesses or known HIV disease\n             requiring antiretroviral treatment.\n\n          -  Any severe acute or chronic medical condition which could impair the ability of the\n             patient to participate in to the study or interfere with interpretation of study\n             results, or patient unable to comply with the study procedures.\n\n          -  Concomitant treatment with biphosphonates or denosumab except if the dose has been\n             stable for 12 weeks prior to enrollment\n\n          -  Absence of signed and dated Institutional Review Board (IRB)-approved patient\n             informed consent prior to enrollment into the study.\n\n          -  Patients with reproductive potential who do not agree to use an accepted and\n             effective method of contraception during the study treatment period. The definition\n             of \"effective method of contraception\" will be based on the investigator's judgment.\n\n          -  History of hypersensitivity to docetaxel or polysorbate 80.\n\n          -  Inadequate organ and bone marrow function\n\n          -  Contraindications to the use of corticosteroid treatment\n\n          -  Symptomatic peripheral neuropathy grade >2 (NCI CTCAE v.4.03).\n\n          -  Treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a\n             two-week wash-out period is necessary for patients who are already on these\n             treatments)\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718353", 
            "org_study_id": "CABAZL06056", 
            "secondary_id": "U1111-1130-9893"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cabazitaxel plus prednisone", 
                "description": "Pharmaceutical form: solution Route of administration: intravenous", 
                "intervention_name": "CABAZITAXEL (XRP6258)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Docetaxel plus prednisone", 
                "description": "Pharmaceutical form: solution Route of administration: intravenous", 
                "intervention_name": "DOCETAXEL (XRP6976)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Docetaxel plus prednisone", 
                    "Cabazitaxel plus prednisone"
                ], 
                "description": "Pharmaceutical form: tablet Route of administration: oral", 
                "intervention_name": "prednisone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Prednisone", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-3300"
                    }, 
                    "name": "Investigational Site Number 840003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Investigational Site Number 840016"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salinas", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93901"
                    }, 
                    "name": "Investigational Site Number 840011"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20016-2695"
                    }, 
                    "name": "Investigational Site Number 840102"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Investigational Site Number 840005"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metairie", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70006"
                    }, 
                    "name": "Investigational Site Number 840025"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Annapolis", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21401"
                    }, 
                    "name": "Investigational Site Number 840020"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21230"
                    }, 
                    "name": "Investigational Site Number 840002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20817"
                    }, 
                    "name": "Investigational Site Number 840007"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20850"
                    }, 
                    "name": "Investigational Site Number 840017"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Investigational Site Number 840023"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cherry Hill", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08003"
                    }, 
                    "name": "Investigational Site Number 840010"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Orange", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07018"
                    }, 
                    "name": "Investigational Site Number 840015"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Investigational Site Number 840019"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Investigational Site Number 840001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029-6574"
                    }, 
                    "name": "Investigational Site Number 840013"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43219"
                    }, 
                    "name": "Investigational Site Number 840008"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29414"
                    }, 
                    "name": "Investigational Site Number 840009"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Myrtle Beach", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29572"
                    }, 
                    "name": "Investigational Site Number 840021"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Investigational Site Number 840012"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53705"
                    }, 
                    "name": "Investigational Site Number 840004"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "zip": "T6G 1Z2"
                    }, 
                    "name": "Investigational Site Number 124001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitchener", 
                        "country": "Canada", 
                        "zip": "N2G1G3"
                    }, 
                    "name": "Investigational Site Number 124003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "zip": "H2W1S6"
                    }, 
                    "name": "Investigational Site Number 124002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "zip": "H2L 4M1"
                    }, 
                    "name": "Investigational Site Number 124004"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "PSA response rate", 
                "safety_issue": "No", 
                "time_frame": "Every 3 weeks, up to max 5 years"
            }, 
            {
                "measure": "Circulating tumor cells (CTCs) with response to docetaxel or cabazitaxel treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to max 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718353"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to max 5 years"
            }, 
            {
                "measure": "PSA progression-free survival rate", 
                "safety_issue": "No", 
                "time_frame": "up to max 5 years"
            }, 
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "up to max 5 years"
            }, 
            {
                "measure": "Radiographic progression-free survival (rPFS) rate", 
                "safety_issue": "No", 
                "time_frame": "up to max 5 years"
            }, 
            {
                "measure": "Clinical progression-free survival (cPFS)", 
                "safety_issue": "No", 
                "time_frame": "up to max 5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to max 5 years"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}